Hemoglobin-Based Oxygen Carriers: History, Limits, Brief Summary of the State of the Art, Including Clinical Trials

Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood

Volumn , Issue , 2011, Pages 301-316

  Jahr, Jonathan S ^a   Sadighi, Arezou ^a   Doherty, Linzy ^a   Li, Alvin ^b   Won Kim, Hae ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Allogeneic RBC transfusion risks infectious transmission, transfusion related acute lung injury (TRALI); American Society of Anesthesiologists guidelines, for RBCs transfusion; Blood transfusion limitations longevity of blood, rigorous crosstype matching; HBOC research, in future concerted effort, industry collaboration with academic centers; Hemoglobin based oxygen carriers state of the art, clinical trials; Human polymerized hemoglobin; Maleimide polyethylene glycol modified Hb (MP4) oxygen carrying plasma expander; Red blood cell (RBC) transfusion life saving, multiple risks

Indexed keywords

EID: 84865430809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119975427.ch22     Document Type: Chapter

References (45)

1. Greenburg, A.G. and Kim, H.W. Hemoglobin-based oxygen carriers, Crit. Care, 8(Suppl 2), S61-S64 (2004).
2. Jahr, J.S., Walker, V., Manoochehri, K. Blood substitutes as pharmacotherapies in clinical practice, Curr. Opin. Anaesthesiol., 20, 325-330 (2007).
3. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies, an updated report by the american society of anesthesiologists task force on perioperative blood transfusion and adjuvant therapies, Anesthesiology, 105, 198-208 (2006).
4. Weiskopf, R.B., Viele, M.K., Feiner, J. et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia, JAMA, 279, 217-219 (1998).
5. Wettstein, R., Erni, D., Intaglietta, M., Tsai, A.G. Rapid restoration of microcirculatory blood flow with hyperviscous and hyperoncotic solutions lowers the transfusion trigger in resuscitation from hemorrhagic shock, Shock, 6, 641-646 (2006).
6. Jahr, J.S., Moallempour, M., Ellis, J. Transfusion update: triggers, targets and will we ever have a blood substitute?, Curr. Rev. Clin. Anest., 28, 251-256 (2008).
7. Cohn, S.M. Blood substitutes in surgery, Surgery, 127, 599-602 (2000).
8. Miller, R.D., Eriksson, L.I., Fleisher, L.A., et al. Miller's Anesthesia, 7 edn, Churchill Livingstone, Philadelphia, PA (2010).
9. Amberson, W. Blood substitutes, Biol. Rev., 12, 48-86 (1937).
10. Spahn, D.R., Kocian, R. Artificial O2 carriers: status in 2005, Curr. Pharm. Design, 11, 4099-4114 (2005).
11. Jahr, J.S., Nesargi, S.B., Lewis, K., Johnson, C. Blood substitutes and oxygen therapeutics: an overview and current status, Am. J. Ther., 9, 438-439 (2002).
12. Saxena, R., Wijnhoud, A.D., Carton, H., et al. Controlled safety study of a Hemoglobin-Based Oxygen Carrier, DCLHb, in acute ischemic stroke, Stroke, 30, 993-996 (1999).
13. Sloan, E.P., Koenigsberg, M., Gens, D., et al. Diaspirin Cross-Linked Hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial, JAMA, 282, 1857-1864 (1999)
14. Burhope, K., Gordon, D., Estep, T. Review of hemoglobin-induced myocardial lesions, Artif. Cell. Blood Sub. Biotechnol., 32, 353-374 (2004).
15. Cheng, D.C., Mazer, C.D., Martineau, R., et al. A phase II dose-response study of Hemoglobin Raffimer (Hemolink) in elective coronary artery bypass surgery, J. Thorac. Cardiov. Sur., 127, 79-86 (2004).
16. Greenburg, A.G., Kim, H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. The Hemolink Study Group, J. Am. Coll. Surgeons, 198, 373-383 (2004).
17. Gould S.A, Moore, E.E., Hoyt, D.B., et al. The life-sustaining capacity of Human Polymerized Hemoglobin when red cells might be unavailable, J. Am. Coll. Surgeons, 195, 445-455 (2002).
18. Moore, E.E., Moore, F.A., Fabian, T.C., et al. Human Polymerized Hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. The PolyHeme Study Group, J. Am. Coll. Surgeons, 208, 1-13 (2009).
19. Jahr, J.S., Varma, N., PolyHeme Northfield Laboratories, IDrugs, 7, 478-482 (2004).
20. Jahr, J.S., Moallempour, M., Lim, J.C. HBOC-201, hemoglobin glutamer-250, Hemopure, Expert Opin. Biol. Th., 8, 1425-1433 (2008).
21. Jahr, J.S., Mackenzie, C., Pearce, L.B., et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery, J. Trauma, 64, 1484-1497 (2008).
22. Dube, G.P., Vranckx, P., Greenburg, A.G. HBOC-201: the multi-purpose oxygen therapeutic, Eurointervention, 4, 161-165 (2008).
23. Olofsson, C., Nygards, E.B., Ponzer, S., et al. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopedic surgery patients with spinal anesthesia, Transfusion Med., 18, 28-39 (2008).
24. Bjorkholm, M., Fargel, B., Przybelski, R., et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol, Haematologica, 90, 505-515 (2005).
25. Drobin, D., Kjellstrom, B., Malm, E., et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4), J. Appl. Physiol ., 96, 1843-1853 (2004).
26. Olofsson, C., Ahl, T., Johansson, T., et al. A multicenter clinical study of the safety and activity of Maleimide-Polyethylene Glycol-Modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery, Anesthesiology, 105, 1153-1163 (2006).
27. Natanson, C., Kern, S.J., Lurie, P., et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 299, 2304-2312 (2008).
28. Fergusson, D. A., McIntyre, L. The future of clinical trials evaluating blood substitutes, JAMA, 299, 2324-2326 (2008).
29. Levien, L.J., Hodgson, R.E., James, M.F.M. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1295 (2008).
30. Keipert, P.E., Olofsson, C., Winslow, R.M. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1295-1296 (2008).
31. Lewis, R.J., Fost, N. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1296 (2008).
32. Shander, A., Javidroozi, M., Thompson, G. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1296-1297 (2008).
33. Sauaia, A., Moore, E.E., Banerjee, A. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1297 (2008).
34. Sarani, B., Gracias, V. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death, JAMA, 300, 1297-1298 (2008).
35. Natanson, C., Lurie, P., Wolfe, S.M. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death-reply, JAMA, 300, 1298-1299 (2008).
36. Fergusson, D., McIntyre, L. Letters: Hemoglobin-based blood substitutes and risk of myocardial infarction and death-reply, JAMA, 300, 1299 (2008).
37. Natanson, C. Incomplete financial disclosure in a study of cell-free hemoglobin-based blood substitutes and risks of myocardial infarction and death, JAMA, 300, 1300 (2008).
38. Jahr, J.S. Do approved blood substitutes reduce myocardial infarction size: is this the critical question?, Brit. J. Anaesth., 103, 470-471 (2009).
39. Silverman, T.A., Weiskopf, R.B. Hemoglobin-based oxygen carriers: current status and future directions, Anesthesiology, 111, 946-963 (2009).
40. Crawford, M.W., Shichor, T., Engelhardt, T., et al. The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease, Anesthesiology, 107, 281-287 (2007).
41. Fonseca, V., Avizinis, J., Moon-Massat, P., et al. Differential sensitivities of pulmonary and coronary arteries to hemoglobin-based oxygen carriers and nitrovasodilators: study in a bovine ex vivo model of vascular strips, Vasc. Pharmacol., 52, 215-223 (2010).
42. Dennis, A.M., Haselkorn, M.L., Vagni, V.A., et al. Hemorrhagic shock after experimental traumatic brain injury in mice: effect on neuronal death, J. Neurotrauma, 6, 889-899 (2009).
43. Jahr, J.S. Are newer generation hemoglobin-based oxygen carriers safe: do they offer an answer?, Vasc. Pharmacol., 52, 214 (2010).
44. Kim, H.W., Greenburg, A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status, Artif. Organs, 28, 613-828 (2004).
45. Jahr, J.S., Weeks, D.L., Desai, P., et al. Does OxyVita, a new generation hemoglobin-based oxygen carrier, or oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? An ex vivo thrombelastography study, J. Cardiothorac. Vasc. Anesth., 22, 34-39 (2008).